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To assess the potential effect of N-Acteyl-Cysteine (NAC) supplementation on the magnitude of 
EPO response with acute exposure to hypoxia in trained endurance athletes, 10 trained male 
endurance athletes engaged in a placebo-controlled crossover design, featuring two conditions: a 
placebo (PLA) condition and an NAC condition. Each condition featured a day of baseline 
testing followed by an 1800 mg/day supplementation period lasting eight days and, finally, a six-
hour acute hypoxic exposure (FIO2 = 15.8%, ~2500m).  Subject serum EPO (EPO), total 
hemoglobin mass (Hbmass), and hematocrit (Hct) measurements were recorded during the 
baseline visit of each condition in addition to immediately prior to hypoxic exposure in order to 
evaluate changes in subject hematological metrics in response to each supplementation 
condition.  Additionally, EPO was measured every two hours during hypoxic exposure to 
evaluate the EPO response in each condition. Eight days of NAC supplementation prior to acute 
hypoxic exposure did not significantly alter the EPO (IU/L) response between baseline and pre 
hypoxic exposure (10.4±2.9 vs. 9.9±1.5; p=0.52) when compared with the PLA condition 
(10.9±2.5 vs. 10.2±2.0; p=0.23).  Additionally, no significant changes were seen in Hbmass 
(g/kg) in the NAC condition (15.75±0.97 vs 16.01±0.68; p=0.58) when compared to the PLA 
condition (15.58±0.72 vs 15.84±0.97; p=0.24). Finally, no significant changes were seen in 
hematocrit (%) in the NAC condition (46.2±1.6 vs 46.6±1.9; p= 0.57) when compared to the 
PLA condition (45.8±2.7 vs 46.4±2.2; p=0.23). EPO increased at each time point after tent entry 
in both conditions but the magnitude of increase (NACΔ 32.3±23.6% vs PLAΔ 31.4±20.9%) was 
not significantly different between conditions. NAC supplementation prior to acute hypoxic 
exposure has no significant impact on EPO concentration in trained endurance athletes. The large 
variation in intra-subject EPO response to hypoxia between conditions may have concealed any 
impact that NAC supplementation had on EPO response.    
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Since the mid-1960s, elite endurance athletes have attempted to enhance exercise 
performance at sea level through the use of chronic hypoxic exposure.  As a result, the validity 
and efficacy of manipulating hypoxic exposure to enhance performance has been a subject 
frequently studied within the scientific community.  Research in this field has highlighted the 
many physiological adaptations to hypoxic exposure (Chapman, Stray-Gundersen, and Levine 
1998; B. Levine and Stray-Gundersen 1992; Naeije 2010; Wilber 2007).  Perhaps the most 
important adaptation, in regards to endurance performance, is the marked expansion in 
hemoglobin mass associated with chronic exposure to hypoxia (Chapman et al. 2014; Chapman, 
Stray-Gundersen, and Levine 1998; B. D. Levine and Stray-Gundersen 1997; B. Levine and 
Stray-Gundersen 1992; Wilber 2007).  This hematological response enhances the oxygen 
carrying capacity of the blood; which is widely considered to be the primary performance 
enhancing outcome of chronic altitude training by endurance athletes (Chapman et al. 2014; 
Chapman, Stray-Gundersen, and Levine 1998; B. Levine and Stray-Gundersen 1992). 
Investigations into the optimization of the hematological profile in response to hypoxia 
have largely centered on enhancing the production of the protein/hormone erythropoietin (EPO), 
which serves as the primary control for the expansion of red blood cells and hemoglobin mass 
(Bauer 1988; Eckardt 1989; Fisher 1983).  EPO production occurs within the adrenal cortex and 
is mediated by a number of factors, most notably, the stabilization of Hypoxia Inducible 
Transcription Factor (HIF-1α) (C Bauer 1988; Christian Bauer and Kurtz 1989; Fisher 1983).  
HIF-1α stabilizes in response to a mismatch between oxygen demand and oxygen 
availability, as perceived by oxygen sensing mechanisms located within the body (Harms and 




Stager 1995; Huang et al. 1996).  The rapid degradation period of stabilized HIF-1α under 
normoxic conditions presents a challenge to athletes attempting to enhance EPO production (Lee 
et al. 2004). Ultimately, since the EPO response to hypoxia is proportional to the level of 
hypoxic stress, athletes could simply maximize EPO production by living at higher elevations 
(Stager 1995; Huang et al. 1996).  However, living at elevations above 2500 meters is associated 
with acute and chronic acclimatization processes which may be detrimental to both health and 
training status (Bärtsch and Saltin 2008; Hackett and Roach 2001; Roach et al. 2000; Schneider 
et al. 2002).  Furthermore, endurance athletes living above 2500 meters may struggle to train at 
the intensities necessary to maintain sea level performance (Chapman et al. 2014; Chapman, 
Stray-Gundersen, and Levine 1998; B. D. Levine and Stray-Gundersen 1997).  It stands to reason 
then, that elite endurance athletes engaging in hypoxic training should explore methods of 
enhancing the EPO response beyond merely attempting to live at increasingly greater elevations. 
Select dietary interventions in concert with exposure to moderate hypoxia (2000-2500m) may be 
a simple and relatively easy method to achieve this outcome and, subsequently, enhance 
performance.  
Research into the antioxidant, N-Acetyl-Cysteine (NAC) has suggested that the readily 
available, over-the-counter cysteine supplement, works as a mild stabilizer of HIF-1α 
(Hildebrandt et al. 2002; A Zembron-Lacny et al. 2010).  The cysteine sulfanyl group has been 
shown to alter the thiol content of the blood, primally through the generation of glutathione with 
NAC supplementation, thereby altering the oxygen sensing ability of the chemoreceptors in the 
body (Hildebrandt et al. 2002; Momeni et al. 2011; Tajima et al. 2009). This is thought to 
stabilize HIF-1α and, subsequently, upregulate EPO production (Hildebrandt et al. 2002; A 
Zembron-Lacny et al. 2010). To date investigations into NAC and its potential role in the EPO 




production have been limited to diseased or untrained populations (Hildebrandt et al. 2002; 
Momeni et al. 2011; Agnieszka Zembron-Lacny et al. 2009).  Further, studies into the effect of 
anti-oxidant supplementation on EPO response to hypoxic environments have not included 
trained athletes (Hildebrandt et al. 2002; Momeni et al. 2011; Agnieszka Zembron-Lacny et al. 
2009).   
Statement of the Problem 
 Due to an individualized physiological response, trained endurance athletes may struggle 
to optimize desired hematological adaptations derived from exposure to hypoxia.  
Purpose of the study 
 The purpose of this study is to explore the potential augmentative effect of the 
antioxidant N-Acetyl-Cysteine on the magnitude of EPO response with acute exposure to 
hypoxia in elite endurance athletes. 
Significance of the study 
 A large portion of trained endurance athletes utilize hypoxic exposure as a means to 
augment hematological markers that impact performance (Chapman et al. 2014; Chapman, 
Stray-Gundersen, and Levine 1998).  As a result of the individualized response to hypoxia, many 
endurance athletes struggle to optimize hematological adaptations to hypoxic exposure 
(Chapman, Stray-Gundersen, and Levine 1998; Harms and Stager 1995).  If dietary 
interventions, such as NAC supplementation, are able to augment the EPO response, elite 









1. Subjects selected for this study will be highly trained endurance athletes. 
2. Medical grade assays will be used in an effort to ensure a quality measurement of blood 
markers. 
3. The study will rely on the use of randomized, repeated measures, cross-over study design 
where subjects will serve as their own control group in an attempt to control for an 
individualized response to hypoxia. 
Limitations 
1. The sample size of the study will be small and may impact the any statistical conclusions 
drawn from the results. 
2. The fitness level between subjects may vary and affect the ability to generalize findings to 
elite athletes. 
Assumptions 
1. We assume that all subjects selected to participate in this study are highly trained 
endurance athletes. 
2.  We assume that all subjects are healthy and free from any neuroendocrine limitation that 
might constrain their response to hypoxia. 
3. We assume that exposure to both normobaric and hypobaric hypoxia result in identical 
physiological responses. 
Specific Aim and Hypothesis 
Specific Aim: To determine whether or not prior NAC supplementation augments the EPO 
response to hypoxia in highly trained endurance runners 
Research hypothesis for specific aim: 




Eight days of NAC supplementation prior to hypoxic exposure will augment the magnitude of 
the EPO response to 6 hours of acute hypoxic exposure beyond placebo supplementation in elite 
endurance athletes.  
Definition of Terms 
Erythropoietin (EPO): The protein/hormone responsible for upregulating the production of 
hemoglobin mass and red blood cells. 
Anti-oxidant: A substance that remedies oxidative stress and neutralizes free radicals. 
N-Acetyl-Cysteine (NAC): A commercially available, anti-oxidant supplement. 
Hypoxic Inducible Transcription Factor (HIF-1α): The protein responsible for upregulating 
the production of EPO when stabilized. 
Hematological Adaptations: Changes in the blood markers as a result of a given stimuli.  
Reactive Oxygen Species (ROS): Reactive molecules and free radicals derived from molecular 
oxygen.   
Hypoxia: Deficiency in atmospheric oxygen; 15.8% Po2 














REVIEW OF LITERATURE 
Introduction 
Hypoxic training has become a common practice amongst elite endurance athletes hoping to 
enhance endurance sport performance(Wilber 2007).  The primary hematological adaptation to 
hypoxia that is associated with endurance sport performance, increased red cell and hemoglobin 
mass, is reliant upon the stability of HIF-1α(Fisher 1983; Koh, Spivak-Kroizman, and Powis 
2008; B. Levine and Stray-Gundersen 1992; Naeije 2010). The induction status of HIF-1α serves 
as the signal for the production of EPO within the renal cortex, which initiates the erythropoietic 
process(Christian Bauer and Kurtz 1989; Fisher 1983; Naeije 2010).  With that being said, the 
relative instability of HIF-1α in concert with the highly variable and individualized response to 
hypoxia presents a problem for athletes when prescribing guidelines for hypoxic 
training(Chapman, Stray-Gundersen, and Levine 1998; Wilber 2007).  HIF-1α stabilization is 
mediated by a number of oxygen dependent process and thus, the erythropoietic response to 
hypoxia is proportional to the level of perceived hypoxic stress (Eckardt 1989; Koh, Spivak-
Kroizman, and Powis 2008). There are, however, functional limitations in maximizing 
erythropoiesis by maximizing hypoxic stress and athletes should be made aware of potential 
adverse consequences associated with living and training at elevations greater than 2500 meters 
(Bärtsch and Saltin 2008; Buskirk et al. 1967; Harms and Stager 1995; B. Levine and Stray-
Gundersen 1992; Roach et al. 2000; Schneider et al. 2002).  Due to these contraindications, 
athletes may want to seek interventional methods designed augment the erythropoietic response 
to hypoxia at elevations below 2500 meters(Chapman et al. 2014; B. Levine and Stray-
Gundersen 1992; B. D. Levine and Stray-Gundersen 2006; Wilber 2007).  It is then the purpose 




of this review to explore the validity and efficacy of two dietary interventions which may 
augment the erythropoietic response to a fixed level of moderate hypoxia.  Relevant literature 
regarding the following topics will be carefully considered: (1) A brief review of hypoxic 
training models (2) HIF-1α and its role in erythropoiesis (3) N-Acetyl-Cysteine as a mild HIF-1α 
stabilizer.   
Approaches to Hypoxic Training 
 In the mid-1960s, athletes and coaches started to utilize hypoxic training as means to 
improve performance in hypoxia.  Over time, this focus has morphed into utilizing hypoxic 
training as a means to enhance normoxic performance and has grown to become common 
practice amongst endurance athletes as a means to enhance performance in recent years.  As a 
result, the physiological response to hypoxia as it relates to endurance sport performance has 
been a heavily researched topic amongst sport scientists (Chapman, Stray-Gundersen, and 
Levine 1998; B. Levine and Stray-Gundersen 1992; Wilber 2007).  This expansion of research 
into hypoxic training has yielded many training models, two of which will be compared for the 
purposes of this review; the live high, train high (LHTH) and live high, train low (LHTL) models 
(Wilber 2007).  The contradictory nature of these models has led to much debate within the 
scientific community as to the best practice protocol for hypoxic training to improve endurance 
performance (B. Levine and Stray-Gundersen 1992; Wilber 2007).  While it is widely accepted 
that the hematological adaptions that occur in response to hypoxia are beneficial for 
performance, evidence has suggested that impaired training during periods of hypoxic exposure 
can have a negative impact on performance (Buskirk et al. 1967; B. D. Levine and Stray-
Gundersen 1997; Naeije 2010; Niess et al. 2003; Roach et al. 2000; Wilber 2007).  




The LHTH model of hypoxic training is considered to be the original hypoxic training 
protocol and is characterized by long periods of living and training at moderate to high 
elevations (1500-4000m)(Wilber 2007).  Consensus on the effectiveness of LHTH models is 
lacking, due to a number of study design issues such as group training effects, training camp 
effects, fitness prior to the start of altitude training, iron status, and adequate (Duke, Chapman, 
and Levine 2012).  However, part of any lack of improvement after LHTH is likely the result of 
an inability to match sea level training intensities and skeletal muscle oxygen flux at moderate 
elevations (2500m) (Buskirk et al. 1967; Chapman et al. 2014; Harms and Stager 1995; B. D. 
Levine and Stray-Gundersen 1997; Niess et al. 2003; Roach et al. 2000).  In addition to training 
impairment, there is a growing body of evidence highlighting the contraindicated health effects 
to living and training above moderate to high elevations (Bärtsch and Saltin 2008; Hackett and 
Roach 2001; Roach et al. 2000; Schneider et al. 2002). Chief among these is acute mountain 
sickness, which has been experienced by elite athletes living and training at elevations as low as 
2500m (Bärtsch and Saltin 2008; Hackett and Roach 2001; Roach et al. 2000; Schneider et al. 
2002). Furthermore, the high intensity training needed to produce elite level performance may 
exacerbate negative health outcomes (Hackett and Roach 2001; Roach et al. 2000).  
 The live-high, train-low (LHTL) approach to altitude training offers a potential solution, 
as athletes are able to optimize hematological adaptations by living at moderate elevations while 
maintaining the necessary training intensities and oxygen uptakes by training at lower elevations 
(Chapman et al. 2014; B. Levine and Stray-Gundersen 1992; B. D. Levine and Stray-Gundersen 
1997; Wehrlin et al. 2006; Wilber 2007).  The LHTL model has been shown in a number of 
studies to have a positive impact on both hematological and performance outcomes(Chapman et 
al. 2014; B. Levine and Stray-Gundersen 1992; B. D. Levine and Stray-Gundersen 1997; 




Wehrlin et al. 2006; Wilber 2007).  With that being said, due to the highly variable and 
individualized physiological response to hypoxia, limitations to the overall effectiveness of 
current LHTL model are likely to exist (Chapman, Stray-Gundersen, and Levine 1998; B. Levine 
and Stray-Gundersen 1992).  While the physiological response to hypoxia is proportional to level 
of perceived hypoxic stress, contraindications experienced by living and training above 2500m 
may negate any hematological benefit gained from simply increasing hypoxic stress (Bärtsch and 
Saltin 2008; Buskirk et al. 1967; Eckardt et al. 1989; Roach et al. 2000; Wilber 2007).  Athletes 
hoping to maximize the hematological and performance outcomes in response to hypoxic 
training may benefit from interventions designed to augment the physiological response to 
hypoxia without risking the previously noted contraindications.  Such interventions could be 
optimized if there was greater understanding of the manipulate factors associated with the 
production of erythropoietin and its transcriptional controller HIF-1α.   
HIF - 1α and its role in erythropoiesis: 
HIF-1α serves as the master control of cellular hypoxic response and is responsible for 
the transcription of over 100 genes required for hypoxic adaptation including the upregulation of 
EPO production (Koh, Spivak-Kroizman, and Powis 2008; Tajima et al. 2009).  In regards to 
endurance sport performance, the most important of these outcomes is the upregulation of EPO 
production; which occurs within the renal cortex (Chapman, Stray-Gundersen, and Levine 1998; 
Fisher 1983; B. Levine and Stray-Gundersen 1992; Naeije 2010; Wilber 2007).  The 
protein/hormone EPO serves to signal the expansion of both hemoglobin and red cell mass.  This 
works to enhance the oxygen carrying capacity of the blood, which is widely accepted as the 
most important factor in aerobic performance(Fisher 1983; B. D. Levine and Stray-Gundersen 
2006).  Furthermore, the magnitude of the physiological response triggered by HIF-1α 




stabilization has been proven to be directly proportional to the amount of hypoxic stress placed 
upon it (Eckardt et al. 1989).  As a result, endurance athletes training in hypoxia have indirectly 
sought to maximize the length and intensity of HIF-1α stabilization in an effort to optimize the 
physiological adaptations to hypoxia (Chapman et al. 2014; B. D. Levine and Stray-Gundersen 
2006).   
The rapid degradation and relatively short half-life of activated HIF-1α presents a 
challenge to these athletes (Koh, Spivak-Kroizman, and Powis 2008; Lee et al. 2004; B. D. 
Levine and Stray-Gundersen 2006; Wilber 2007).  HIF-1α stabilization is known to mediated by 
a number of oxygen dependent pathways and thus relies on the ability of cells to sense changes 
in rapidly changing oxygen levels (Christian Bauer and Kurtz 1989; Koh, Spivak-Kroizman, and 
Powis 2008; Lee et al. 2004).  Perhaps the most notable of these pathways involves the ubiquitin 
degradation by the Von Hippel Lindau (pVHL) protein (Chandel et al. 2000; Jaakkola et al. 
2001; Koh, Spivak-Kroizman, and Powis 2008; Li et al. 2005; Ohh et al. 2000).  Under normoxic 
conditions, prolyl hydroxylases (PHD1, PHD2, and PHD3) work to hydroxylate HIF-1α, and this 
results in the binding of pVHL to the HIF-1α oxygen-dependent domain (ODD) (Chandel et al. 
2000; Jaakkola et al. 2001; Koh, Spivak-Kroizman, and Powis 2008; Li et al. 2005; Ohh et al. 
2000).  Once bound to pVHL, this complex is targeted for destruction via the ubiquitin pathway 
in the proteasome (Jaakkola et al. 2001; Koh, Spivak-Kroizman, and Powis 2008; Li et al. 2005; 
Ohh et al. 2000).  Recent evidence has suggested that prolyl hydroxylase activity may be 
dependent upon reactive oxygen species (ROS) released from mitochondrial complex III during 
aerobic metabolism for oxygen sensing and, subsequently, HIF-1α hydroxylation (Chandel et al. 
2000; Jaakkola et al. 2001; Koh, Spivak-Kroizman, and Powis 2008; Simon 2006).   Conversely, 
in hypoxic conditions, PHD activity is inhibited; perhaps by a shift towards a higher reliance 




upon anaerobic metabolism at the cellular level( Chandel et al. 2000; Koh, Spivak-Kroizman, 
and Powis 2008; Li et al. 2005; Ohh et al. 2000).  This creates a blunted ROS response from 
mitochondrial complex III, preventing pVHL binding to HIF-1α and resulting in HIF-1α 
stabilization (Jaakkola et al. 2001; Koh, Spivak-Kroizman, and Powis 2008; Ohh et al. 2000).  
Upon stabilization, HIF-1α dimerizes with HIF-1β and is translocated to the nucleus, stimulating  
DNA transcription and  upregulation of EPO production via REDOX sensitive pathways (Huang 
et al. 1996; Koh, Spivak-Kroizman, and Powis 2008; Tajima et al. 2009).  The interaction 
between these outcomes appear plays an important role in determining the hematological 
adaptions in response to hypoxia (Koh, Spivak-Kroizman, and Powis 2008; Tajima et al. 2009). 
The upregulation of EPO production within the renal cortex as the result of HIF-1α 
induction works to stimulate the formation of erythrocytes within the bone marrow (C Bauer 
1988; Christian Bauer and Kurtz 1989; Naeije 2010). The magnitude of the EPO response is 
proportional to perceived hypoxic stress and peaks around 30 hours in response to prolonged 
hypoxia (Eckardt et al. 1989; Garvican et al. 2012; Tajima et al. 2009).  The erythropoietic 
process, however, has been shown to take up to 7-10 days while hypoxic training studies have 
shown appreciable gains in both red cell and hemoglobin mass only after 3-4 weeks of hypoxic 
exposure (Chapman et al. 2014; B. D. Levine and Stray-Gundersen 2006; Naeije 2010; Wilber 
2007). Thus, to achieve optimal hematological and performance outcomes, athletes should seek 
to maximize the EPO response to hypoxia. 
The initial magnitude of EPO production in response to hypoxia dictates the intensity of 
the hematological, and subsequent, performance response (Eckardt et al. 1989; B. Levine and 
Stray-Gundersen 1992; Wilber 2007).  Since adverse effects to living at elevations above 2500 
meters are likely to mitigate the performance benefits of hypoxic training in areas of high 




hypoxic stress, a secondary approach might be to maximize any potential benefits through 
nutritional supplements directed at the underlying biochemical mechanisms.  (2000-2500m) 
(Bärtsch and Saltin 2008; Buskirk et al. 1967; Hackett and Roach 2001; Harms and Stager 1995; 
Niess et al. 2003; Roach et al. 2000; Schneider et al. 2002).   
NAC as a HIF-1α stabilizer 
Research into the antioxidant, N-Acetyl-Cysteine (NAC) has suggested that the over-the-
counter supplement works as a mild stabilizer of HIF-1α (Hildebrandt et al. 2002; Agnieszka 
Zembron-Lacny et al. 2009; A Zembron-Lacny et al. 2010).  The antioxidant properties of NAC 
work by scavenging ROS and serve as a membrane permeable precursor to glutathione (Chandel 
et al. 2000; Hildebrandt et al. 2002; Tajima et al. 2009; A Zembron-Lacny et al. 2010).  Within 
the pVHL pathway, NAC supplementation works to scavenge the ROS produced within 
mitochondrial complexes I & III (Chandel et al. 2000; Hildebrandt et al. 2002; A Zembron-
Lacny et al. 2010).  The scavenging of mitochondrial ROS inhibits PHD activity and 
subsequently, the hydroxylation of HIF-1α (Chandel et al. 2000; Hildebrandt et al. 2002; Koh, 
Spivak-Kroizman, and Powis 2008; Ohh et al. 2000).  This results in the down-regulation of 
pVHL and the catabolism of HIF-1α via the ubiquitin proteasome pathway.  Therefore, NAC 
leads to ROS scavenging and stabilization of HIF-1α (Chandel et al. 2000; Koh, Spivak-
Kroizman, and Powis 2008; Li et al. 2005; Ohh et al. 2000).   
With NAC’s role in the pVHL ubiquitin pathway in mind, there are two key studies 
which show promise for endurance athletes seeking to optimize hematological factors associated 
with performance. The first of these studies was the work of Zembron-Lacny et al. (2010) in 
which the effects of NAC supplementation on blood thiol and plasma EPO concentrations in 
healthy individuals under normoxic conditions were examined in a placebo-controlled design. 




Subjects in the experimental group underwent an 8-day supplementation period in which they 
consumed 1200 mg/d of NAC.  Blood measures collected at the end of the supplementation 
period within the NAC group displayed a significant rise in both plasma EPO and total thiol 
concentrations over values collected from the placebo group.  Furthermore, the relationship 
between total thiol and plasma EPO concentrations can be seen in the figure below. 
  
Figure 1. Relationship between total thiols and EPO (erythropoietin) concentration. From Zembron-Lacny 
et al., 2008 
 
In regard to endurance sport performance, these findings seem to indicate that NAC may be able 
to enhance EPO production in a manner independent of hypoxic stress; perhaps through the 
manipulation of plasma thiol content and its known degradation of the pHVL pathway.  In 
theory, a shift in blood thiol content could augment the hematological response to hypoxia 
without inducing additional hypoxic stress.  In the second of these studies, Hildebrandt et al. 
(2001) sought to assess the hematological effects of a 5-day, placebo controlled,1800 mg/d NAC 
supplemental period prior acute exposure (6hrs) to normobaric hypoxia (FiO2 ~ 14%).  Blood 
measures of EPO and thiol concentrations were taken on days 1 and 5 of the supplemental period 
and at 8 different time points during exposure to hypoxia.  These samples demonstrated a 




significant change in both thiol and EPO concentration between the NAC and control groups as 






















Longitudinal changes during NAC treatment and prolonged poikilocapnic hypoxia. Values are means ± 
SEM of the data before (day 1) and after 4 days of treatment (day 5) and the data on day 6 before, during, and after a 




6-hour exposure to prolonged hypoxia indicated by the windows. The 6-hour exposition to normobaric hypoxia on 
day 6 started at 10 AM. Three subjects (all placebo) of the total group (n = 26) refused to participate in the hypoxic 
exposition. Significant differences between the NAC group (●) and the placebo group (○) (*P < .05; **P < .01), 
significant changes compared with corresponding time points on day 1 (#P < .05; ##P < .01), and significant 
posthypoxic changes compared with the last value in hypoxia (day 6, 3:30 PM) ($P < .05; $$ P < .01) are indicated 
 
Taken together, these studies highlight the augmentative effect that NAC has on 
erythropoiesis under both normoxic and hypoxic conditions. However, both studies are limited in 
regards to their application to elite athletes as the subjects in the study were described as ‘normal 
and untrained’ (Hildebrandt et al. 2002; Agnieszka Zembron-Lacny et al. 2009).  With that being 
said, it stands to reason that the consequential shift towards anaerobic metabolism in response to 
hypoxia that reduces the ROS output from mitochondrial complex III might be augmented 
further by the ROS scavenging properties of NAC supplementation regardless of training status. 
(Chandel et al. 2000; Hildebrandt et al. 2002; Koh, Spivak-Kroizman, and Powis 2008; 
Agnieszka Zembron-Lacny et al. 2009).  Additionally, the increase in blood GSH in response to 
NAC supplementation might elongate the peak EPO response to hypoxia (Ferrara, Gerber, and 
LeCouter 2003; Hildebrandt et al. 2002; Huang et al. 1996; Tajima et al. 2009).  While mild 
adverse effects have been reported with intravenous supplementation, no adverse effects have 
been reported with oral NAC supplementation (Rhodes and Braakhuis 2017).  
Conclusions and Rationale for the Study 
 Hypoxic training has been proven to be an effective way to enhance endurance sport 
performance through the optimization of the hematological profile (B. Levine and Stray-
Gundersen 1992; Wehrlin et al. 2006; Wilber 2007).  Due to a number of adverse effects of 
living and training above 2500m, elite endurance athletes may benefit from interventional 
methods designed to optimize the hematological benefits of living at moderate elevations (2000-
2500m) (Chapman et al. 2014; B. D. Levine and Stray-Gundersen 1997; Roach et al. 2000; 




Wilber 2007).  The control for EPO production is mediated by the stabilization status of the α-
subunit of HIF-1 (Fisher 1983).  Supplementation with NAC may work to aid in the stabilization 
of HIF-1α through the scavenging of ROS released by mitochondrial complex III (Chandel et al. 
2000; Hildebrandt et al. 2002).  Furthermore, NAC supplementation is a known, membrane–
permeable, precursor to GSH and works to alter the thiol content of the blood (Hildebrandt et al. 
2002; Tajima et al. 2009; Agnieszka Zembron-Lacny et al. 2009; Zembron-Lacny et al. 2010).  
This is believed to enhance the stabilization of HIF-1α in hypoxia, further augmenting the 
erythropoetic response.(Ferrara, Gerber, and LeCouter 2003; Huang et al. 1996; Tajima et al. 





















Selection of Subjects: 16 well-trained male endurance athletes from Indiana University and the  
surrounding Bloomington area were recruited for participation in this study.  Inclusion criteria 
was as follows:  Subjects were between 18 and 35 years of age, trained a minimum of 5 days a 
week, and accumulated 300 minutes or more of physical activity weekly.  The Indiana University 
Institutional Review Board approved all protocols and procedures associated with this study and 
subjects gave informed consent prior to the start of all tests.  Subjects were excluded if they 
indicated a history of respiratory, renal, cardiovascular disease, or smoking.  Subjects were also 
be excluded if they have asthma, known allergies to NAC, previous history of acute mountain 
sickness, ulcer or other bleeding disorder, impending surgeries, or conditions where NAC is 
contraindicated – including taking any medications known to have an interaction effect with 
NAC. 
  
Study Design:  Qualifying subjects completed a pseudo-randomized, placebo-controlled cross-
over design.  Subjects engaged in two separate, and blinded experimental conditions:  a placebo 
condition and an NAC condition.  Each experimental condition consisted of a day of baseline 
testing, a treatment period lasting between 8 days, and one or two post-treatment testing sessions.  
In total, subjects were asked to report to the laboratory on eight separate occasions.  A visual 

























Day 1a and 1b: The initial baseline visit included completion of informed consent, and general 
training questionnaire. Additionally, subjects underwent baseline measurements of height, 
weight, body composition, blood collection, and a measure of total hemoglobin mass.  Following 
these measurements on Day 1a, subjects were randomly assigned to counterbalanced groups and 
completed 8 days of blinded supplementation consisting of either NAC or placebo.  Day 1b 
concluded with subjects beginning supplementation of the crossover treatment. 
 
Day 9a and 9b:  Subjects completed a post-supplementation test of total hemoglobin mass. 
 
Day 10a and 10b:   Subjects completed post-supplementation measures of height, weight, and 
body composition.  After a blood draw, participants entered a normobaric hypoxic chamber for 6 
hours and provided a blood sample at 3 additional time points (2,4, and 6 hours).  Arterial 
oxyhemoglobin saturation and heart rate data were collected for the duration of the hypoxic 
session. Following the completion of Day 10a and 10b, subjects engaged in a three-week 
washout period to eliminate any residual effects from the initial supplementation period.   
 
Supplementation: Subjects participating in the NAC group ingested 1800 mg/day in the form of 
three, 600mg doses taken at 8am, 1pm, and 6pm – or with breakfast, lunch and dinner. Subjects 


















on the same time scale. The supplementation period lasted eight days as previous literature has 
shown a significant rise in EPO levels in normoxia following eight days of NAC 
supplementation (Zembron-Lacny et al. 2009).  Subjects were asked to keep a supplementation 
log to ensure compliance and track any missed doses. A three-week washout period was used 
between supplemental periods to ensure that there were no residual effects on future blood 
samples (Zembron-Lacny et al. 2009).  
 
Hypoxic Exposure:  Up to 4 subjects at a time were exposed to six hours of normobaric hypoxia 
using a Colorado Altitude Training Systems altitude chamber (CAT-430, Colorado Altitude 
Training Systems, Boulder, CO).  To simulate hypoxia, a nitrogen generator was used to 
manipulate the atmospheric composition of the chamber to decrease the oxygen partial pressure 
within the tent to 15.8%; the equivalent to an altitude of 2500m / 8000 ft.  To ensure that ambient 
CO2 levels within the chamber were maintained, air was drawn out of the chamber, through a 
CO2 scrubber, and then recirculated back into the chamber.  Subjects were free to stand and 
move about the chamber as needed and fans were placed in the tent to help the subjects stay cool. 
Subjects were given lawn chairs for seating, had access to food and drink, and were free to 
engage in quiet activities in the chamber, including reading, video watching, internet, etc.  
Subjects were asked to void prior to entering the chamber but were asked to wear a face mask 
attached to a reservoir of 15.8% oxygen if they needed to leave the chamber. 
 
SPECIFIC MEASURES 
Height and weight: Height was measured using a stadiometer while weight was recorded using 
an electric scale. 





Body Composition: Body composition was recorded using a bioelectrical impedance device 
Subjects stood on an electrode imbedded scale while holding electrode impeded handles. An 
unnoticeable electric current was briefly sent through the subject from which, impedance was 
measured, and body composition estimated. 
 
Blood sampling:  For each blood sample, approximately 2 – 5 ml was taken via a routine 
venipuncture procedure from an antecubital vein using a 22g or smaller needle and a clot 
activator treated (red top) vacutainer for serum measures and an EDTA treated (purple top) 
vacutainer for reticulocyte measures.  Every effort was made to ensure that blood draws occur at 
the same time during every visit.   
 
Blood processing:  Following manufacturer’s instructions, red top vacutainers (for serum 
samples) were inverted 5 times, allowed 30 minutes to fully clot, then centrifuged for 10 minutes 
at 3000 RPM and 4 degrees C.  Purple top vacutainers (for plasma samples) were inverted 8-10 
times and centrifuged for 10 minutes at 3000 RPM and 4 degrees C.  Serum or plasma was 
aliquoted, labeled, and frozen at -40 degrees C until analyzed.  EPO concentration was 
determined by enzyme-linked immunosorbent assay (ELISA; Human Erythropoietin ELISA Kit 
ab11952, abcam, Cambridge, MA, USA; sensitivity 0.4 mIU/ml; detection range 1.6 – 100 
mIU/ml) with samples analyzed according to manufacturer’s instructions in triplicate using a 
Powerwave XS™ spectrophotometer (Bio-Tek Instruments, Winooski, VT). 
 




 Total hemoglobin mass:  A 2-minute CO rebreathing method, as described by Gore (Gore et al., 
2006) was used to determine total hemoglobin mass.  In brief, subjects inhaled a 1 ml/kg bolus of 
99.5% CO, which was rebreathed for two minutes from a homemade spirometer connected to a 
5L anesthesia bag filled with 100% O2.  Finger prick 100 µL blood samples were collected pre-
rebreathe and 6 and 8 minutes after the beginning of the rebreathe.  These samples were analyzed 
(minimum in triplicate) for carboxyhemoglobin percentage (%HbCO) and hemoglobin 
concentration using a blood gas analyzer (OSM3, Radiometer, Copenhagen).  Measures of end-
tidal CO (Fluke model CO-220, Canada) at minute 5 after the start of the rebreathe, the volume 
of the spirometer post-rebreathe, and CO content of the spirometer post-rebreathe were 
determined.  Assuming an alveolar ventilation of 15 L/min post-rebreathe and a residual volume 
of 1.5 L, total hemoglobin mass was calculated using the equation of Gore et al. (Gore et al., 
2013).    
 
 Arterial Oxyhemoglobin Saturation:  A fingertip pulse oximeter (Masimo Radical 7, Irvine, CA) 
was used to determine arterial oxyhemoglobin saturation in addition to heart rate every 2 hours 
while subjects were in the chamber.   
 
 Treatment of Data:  A 2 x 4 repeated measures ANOVA and Tukey’s post-hoc tests were used 
to assess differences between EPO responses, with treatment group (Placebo, NAC) and hypoxic 
exposure time (0, 2, 4, 6 hours) as within groups independent variables. Additionally, paired 
student’s t-tests with a Bonferoni adjustment for multiple comparisons were used to determine 
differences between baseline and pre-hypoxic exposure timepoints in measures of serum EPO 
and total hemoglobin mass.  




A power analysis used in previous literature (Hildebrandt et al, 2002) indicated that 
approximately 12 subjects would provide adequate statistical power (i.e. 1 – β > 0.80) to show 
significant differences at the p < 0.05 level.  All statistical measures and tests were conducted 


























Subjects:   A total of 16 subjects were recruited for the study.  Six subjects dropped out of 
the study, all due to time constraints, leaving a total of 10 subjects for analysis.  Subject 











 The fractional oxygen content of the tent remained stable throughout all trials and there 
was no significant difference between the PLA and NAC conditions.   
Supplementation:   
 Eight days of NAC supplementation prior to acute hypoxic exposure did not 
significantly alter the serum EPO, hematocrit, or Hb mass in elite endurance athletes when 
compared with the placebo condition as seen in Table 2 below: 
 
Table 1. Subject Characteristics 
Height (m) 1.78 ± 0.03 
Weight (kg) 70.1 ± 4.4 
Body Fat (%) 
 Age (years) 
10.9 ± 2.2 
26.3 ± 4.0 
Values are mean ± SD, N=10 





Hypoxia Exposure Data:   















Values are mean ± SD, N = 10 
EPO - erythropoietin; EPO Δ – percent change in serum EPO from 0h  
* = significantly different from 0hr, within condition 
 
Table 2. Supplementation Blood Data 
Condition PLA Base PLA Pre P-Value NAC Base NAC Pre P-Value 
Hbmas (g/kg) 15.75 ± 0.97 16.01 ± 0.68 0.38 15.58 ± 0.72 15.84 ± 0.97 0.24 
Hematocrit (%) 46.2 ± 1.6 46.6 ± 1.9 0.57 45.8 ± 2.7 46.4 ± 2.2 0.49 
Serum EPO (IU/L) 10.4 ± 2.9 9.9 ± 1.5 0.52 10.9 ± 2.5 10.2 ± 2.0 0.23 
Table 3. Chamber Exposure Data 
Placebo Condition 
Measures 0hr 2hr 4hr 6hr 
Heart Rate (bpm) 60.9 ± 7.6 60.7 ± 7.2 60.6 ± 7.3 62.9 ± 5.3 
Oxygen Saturation (%) 95.3 ± 1.2 95.2 ± 1.1 95.6 ± 1.7 95.2 ± 1.3 
Serum EPO (IU/L) 9.93 ± 1.5 10.8 ± 2.3* 13.1 ± 2.9* 13.1 ± 3.1* 
Serum EPO Δ (%) - 9.3 ± 15.2 32.8 ± 25.0 32.3 ± 23.6 
NAC Condition 
Heart Rate (bpm) 64.3 ± 6.4 68.5 ± 5.1 63.8 ± 6.0 64.8 ± 5.4 
Oxygen Saturation (%) 95.0 ± 1.6 94.8 ± 1.8 95.4 ± 1.5 95.3 ± 1.1 
Serum EPO (IU/L) 10.2 ± 2.0 12.5 ± 4.0* 12.6 ± 2.9* 13.4 ± 2.3* 
Serum EPO Δ (%) - 22.8 ± 19.1 24.1 ± 14.0 31.4 ± 20.9 
Values are mean ± SD, N = 10 
Hbmass - total hemoglobin mass; Serum EPO - erythropoietin; PLA - placebo; NAC-n-acetyl cysteine;  
Base - baseline, prior to supplementation; Pre - pre-tent entry after 8 days of supplementation. 
 




Heart rate and SaO2 were not different at any time point, within either condition.  Serum EPO 
was significantly increased from 0hr (tent entry) at 2h, 4h, and 6h in both conditions; however, 



























 The purpose of this study was to assess the effect of 8 days of NAC supplementation on 
serum EPO production in response to acute hypoxic exposure in trained endurance athletes.  Our 
primary finding is that 8 days of NAC supplementation prior to acute hypoxic exposure has no 
significant impact on serum EPO concentration or erythropoiesis.  The myriad of factors known 
to affect the oxygen cascade, taken in concert with the known individual variance in EPO 
response, suggest the existence of confounding factors beyond the relationship of antioxidant 
status and HIF-1α stabilization regarding EPO production.   
 Trained endurance athletes utilize hypoxic training to increase EPO production and 
ultimately total hemoglobin mass.  Since it has been established that the physiological response 
to hypoxia is proportional to hypoxic stress, one strategy that trained endurance athletes use to 
increase EPO and total Hb mass is to increase the hypoxic dose by living and training at higher 
altitudes (Eckardt et al. 1989).  However, there are outcomes associated with living at altitudes 
above ~2500m which are ultimately negative for exercise performance (Chapman et al, 2016).  
Previous studies indicated that supplementation with NAC prior to acute hypoxic exposure might 
work to stabilize HIF1-α independent of hypoxia (Hildebrandt 2002; Zembron-Lacny 2009) and  
it was hypothesized that a pre-hypoxic, NAC supplementation period might allow for trained 
endurance athletes to maximize EPO response without increasing hypoxic dose.  With that being 
said, despite following a nearly identical supplementation protocol as seen in Zembron-Lacny et 
al. 2009 and Hildebrandt et al. 2002, inter-group differences in mean EPO changes in response to 
the supplementation periods and subsequent acute hypoxic exposures were not found to be 
statistically significant and displayed very large standard deviation values.  Further, intra-group 




mean EPO changes in response to acute hypoxia were statistically significant.  Taken together, 
the data suggest that, while each supplementation group had the expected EPO response to acute 
hypoxia, this response was not significantly different between these groups.         
When considering the large standard deviations seen in the group mean data, it may be 
that they are reflective of the known individualized response to hypoxia within subjects 
(Chapman 1998).  It was assumed that intra-individual serum EPO measures would yield 
consistent results across similar environmental conditions. Subject serum EPO response data, 
however, suggests that intra-individual EPO response may actually be more variable than 
previously thought as subjects experienced an average of 48% variation in EPO response across 
similar environmental conditions.  These data appear to be supported by the conclusions drawn 
from a similar study which showed an average variation of 54% intra-individual EPO response 
(Baranauskas et al, HAMB, in press).   This natural volatility in intra-subject EPO response may 
have concealed any effect that the NAC supplementation period may have had on erythropoiesis 
and may have contributed to the large standard deviations seen in group mean data. 
Limitations: 
 A power analysis using previous literature (Hildebrandt et al, 2002) indicated that 
approximately 12 subjects would provide adequate statistical power (i.e. 1 – β > 0.80) to show 
significant differences at the p < 0.05 level.  The present study recruited 16 individuals but only 
10 individuals finished the study.  A power analysis completed after N=10 indicated that > 100 
subjects would need to be recruited with the observed treatment effect to see statistical 
significance, so a decision was made to terminate the experiment. 
 A hypoxic inspirate of 15.8%, simulating 2500m, was chosen for this study, as this is a 
common altitude utilized by elite endurance athletes when engaged in altitude training.  It is 




possible that with a relatively short exposure duration of 6hr, a larger hypoxic stimulus was 
needed to observe differences in EPO between placebo and NAC conditions. 
Zembron-Lacny et al 2009 and Hildebrandt et al 2002 served as the roadmap for this 
project and both studies measured blood thiol levels both before and after the eight-day 
supplementation period. In hindsight, this data may have given insight into the effect that the 
supplementation period may have had on subject antioxidant status and may have given insight 
into the effectiveness of the NAC dose and the subsequently measured serum EPO response.  
 In conclusion, eight days of supplementation with 1800mg of NAC did not significantly 
alter production of serum EPO after six hours of exposure to a simulated altitude of 2500m in 
elite endurance athletes.  Due to the variance in hematological response experienced by the 
participants in the present study, future studies into the subject matter may look to include 
stricter subject controls in an effort control the large intra-subject variation in EPO response to 
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